KALA BIO, Inc.
No enriched coverage for $KALA in the last 7 days.
No SEC Form 4 filings for $KALA in the last 30 days.
See all $KALA insider activity →KALA BIO (KALA) is seeking shareholder approval for a reverse stock split of up to 1-for-300 at its 2026 annual meeting on November 3. The company also plans to elect directors, vote on executive compensation, and ratify its auditor. KALA recently settled a $2.0 million loan with Oxford, removing debt from its balance sheet.
KALA BIO, Inc. (KALA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 3, 2026, KALA BIO, Inc. (“Kala” or the “Company”) entered into an Exclusive Distribution and Reseller Agreement (the “Agreement”) with Virotek, Inc. (“Virotek”), a Wyoming corporation. The following is a summary
Kala Bio (KALA) and Virotek finalized an exclusive U.S. distribution agreement for Virotek's ophthalmology genetic tests. Kala will market, promote, and distribute the tests, with profit-sharing after Virotek recovers costs. The deal has a one-year term, with exclusivity contingent on commercial milestones. No revenue forecasts were provided. The U.S. genetic testing market was valued at $5.7B in 2025, projected to reach $6.9B in 2026.
Recent KALA coverage spans financial news and corporate actions.
Potential consolidation of shares could lift per‑share price and affect liquidity, but no immediate price move is implied.
Deal creates a conditional exclusivity runway through 9/3/2027, with economics split and a milestone that can downgrade exclusivity to non-exclusive.
Potential revenue upside from exclusive rights to a growing genomic testing market.
Potential near‑term revenue boost from a new diagnostics distribution channel.
Potential suspension of trading pending hearing
AlphAI scores every news story that mentions KALA with an AI model for sentiment and relevance, and aggregates insider trades from KALA BIO, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
KALA BIO (KALA) is seeking shareholder approval for a reverse stock split of up to 1-for-300 at its 2026 annual meeting on November 3. The company also plans to elect directors, vote on executive compensation, and ratify its auditor. KALA recently settled a $2.0 million loan with Oxford, removing debt from its balance sheet.
2 min readKALA BIO, Inc. (KALA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 3, 2026, KALA BIO, Inc. (“Kala” or the “Company”) entered into an Exclusive Distribution and Reseller Agreement (the “Agreement”) with Virotek, Inc. (“Virotek”), a Wyoming corporation. The following is a summary
4 min readKala Bio (KALA) and Virotek finalized an exclusive U.S. distribution agreement for Virotek's ophthalmology genetic tests. Kala will market, promote, and distribute the tests, with profit-sharing after Virotek recovers costs. The deal has a one-year term, with exclusivity contingent on commercial milestones. No revenue forecasts were provided. The U.S. genetic testing market was valued at $5.7B in 2025, projected to reach $6.9B in 2026.
1 min readKala Bio (KALA) and Virotek plan to form a U.S. distribution partnership for Virotek's ophthalmology genetic testing program. Kala will market and distribute the program, leveraging its existing eye care network. The deal is subject to definitive agreements and regulatory approvals, with a target timeline of 30 days. Both companies see this as a strategic fit, with Kala expanding its ophthalmic focus and Virotek gaining U.S. market access.
2 min readKALA BIO received a Nasdaq notice that its stock failed to meet the $1.00 minimum bid price, violating a listing rule. The company is ineligible for the standard compliance period due to a recent reverse split and will request a hearing. The stock will remain listed pending the decision.
1 min readKALA BIO Inc. ( NASDAQ:KALA ) jumped 37.87% to $0.88 in after-hours trading on Tuesday. Check out the current price of KALA stock here. According to Benzinga Pro data, the stock closed the regular session at $0.64, up 3.45%.
3 min readKala Bio Inc. ( NASDAQ: KALA ) stock is down on Monday after the company halted development of its experimental treatment for a specific eye condition. The company had a session volume of 14.04 million compared to the average volume of 216.47 thousand, according to data from Benzinga Pro.
2 min readU.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 150 points on Monday. Following the market opening Monday, the Dow traded up 0.19% to 46,333.68 while the NASDAQ rose 0.67% to 22,635.76. The S&P 500 also rose, gaining, 0.42% to 6,671.51.
3 min readThe mean of analysts' price targets for KALA BIO (KALA) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
5 min readKala Bio ( NASDAQ:KALA ) , a clinical-stage biopharmaceutical company focused on novel therapies for eye diseases, released its second quarter 2025 results on August 8, 2025. The headline was a net loss per share of $1.71 ( GAAP ) . Marginally wider than the analyst estimate of $1.70 ( GAAP ) .
2 min read
